Beijing Aosaikang Pharmaceutical (SHE:002755) said its lieutetinib tablets showed superior efficacy in a phase three clinical trial, with the results published in The Lancet Respiratory Medicine.
The drug demonstrated significantly longer progression-free survival versus gefitinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients, according to a Tuesday filing with the Shenzhen bourse.
Lieutetinib also showed better safety, with lower discontinuation rates and reduced liver toxicity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments